Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemic
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is responsible for the current pandemic, causing so far over 100.000 cases and more than 4500 deaths in Romania. Clinical manifestations are variable, ranging from mild forms (fever, dry cough, dyspnea, tachypnea, asthenia, myalgia) to sev...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Amaltea Medical Publishing House
2020-09-01
|
Series: | Romanian Journal of Rheumatology |
Subjects: | |
Online Access: | https://rjr.com.ro/articles/2020.3/RJR_2020_3_Art-01.pdf |
id |
doaj-72b4a137e2a443a9b1199d919df82998 |
---|---|
record_format |
Article |
spelling |
doaj-72b4a137e2a443a9b1199d919df829982021-09-02T21:56:59ZengAmaltea Medical Publishing HouseRomanian Journal of Rheumatology1843-07912069-60862020-09-0129310111110.37897/RJR.2020.3.1Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemicCatalin Codreanu0Ruxandra Ionescu1Denisa Predeteanu2Elena Rezus3Magda Parvu4Corina Mogosan5Claudiu C. Popescu6Simona Rednic7Romanian Society of Rheumatology; “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; “Dr. Ion Stoia” Clinical Center for Rheumatic Diseases,Bucharest, RomaniaRomanian Society of Rheumatology; “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; „Sf. Maria” Clinical Hospital, Bucharest, Romania Romanian Society of Rheumatology; “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; „Sf. Maria” Clinical Hospital, Bucharest, Romania Romanian Society of Rheumatology; “Grigore T. Popa” University of Medicine and Pharmacy, Iasi, Romania; Clinical Rehabilitation Hospital, Iasi, RomaniaRomanian Society of Rheumatology; “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; Colentina Clinical Hospital, Bucharest, Romania Romanian Society of Rheumatology; “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; “Dr. Ion Stoia” Clinical Center for Rheumatic Diseases,Bucharest, RomaniaRomanian Society of Rheumatology; “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania; “Dr. Ion Stoia” Clinical Center for Rheumatic Diseases,Bucharest, RomaniaRomanian Society of Rheumatology; “Iuliu Hatieganu” University of Medicine and Pharmacy, Cluj-Napoca, Romania; County Emergency Clinical Hospital, Cluj-Napoca, Romania SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is responsible for the current pandemic, causing so far over 100.000 cases and more than 4500 deaths in Romania. Clinical manifestations are variable, ranging from mild forms (fever, dry cough, dyspnea, tachypnea, asthenia, myalgia) to severe bilateral pneumonia (COVID-19). Generally, patients with inflammatory/autoimmune rheumatic diseases have an increased risk of infections compared to the general population, especially if under treatment with immunosuppressive therapies. In the absence of infection or exposure to SARS-CoV-2, the use of specific drugs (non-steroidal anti-inflammatory drugs – NSAIDs; glucocorticoids - GC; conventional synthetic - csDMARDs, targeted synthetic – tsDMARDs and biologic disease-modifying anti-rheumatic drugs - bDMARDs, denosumab) should be unaffected. In patients with exposure to SARS-Co V-2, but without symptoms of COVID-19, NSAIDs, hydroxychloroquine, sulfasalazine and, in specific cases, IL-6 inhibitors may be continued, methotrexate, leflunomide, non-anti-IL-6 bDMARDs, tsDMARDs and immunosuppressants should be temporarily discontinued until a negative result for SARS-CoV-2 or for up to 2 weeks asymptomatic state for specific post-epidemiological COVID-19 symptoms. In patients with confirmed or suspected COVID-19 infection, non-anti-IL-6 bDMARDs, tsDMARDs, methotrexate, leflunomide, sulfasalazine and immunosuppressants must be temporarily discontinued. In such particular cases, IL-6 inhibitors and hydroxychloroquine may be continued, depending on the clinical context. In forms with severe respiratory manifestations, NSAIDs must be stopped. In all cases, non-essential medical consultations and maneuvers should be reduced where appropriate, with optimal use of telemedicine. Social distancing, facial masks and constant hand hygiene is advised for all patients, according to national and international recommendations.https://rjr.com.ro/articles/2020.3/RJR_2020_3_Art-01.pdfsars-cov-2rheumatic diseasesromanian society of rheumatology recommendations |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Catalin Codreanu Ruxandra Ionescu Denisa Predeteanu Elena Rezus Magda Parvu Corina Mogosan Claudiu C. Popescu Simona Rednic |
spellingShingle |
Catalin Codreanu Ruxandra Ionescu Denisa Predeteanu Elena Rezus Magda Parvu Corina Mogosan Claudiu C. Popescu Simona Rednic Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemic Romanian Journal of Rheumatology sars-cov-2 rheumatic diseases romanian society of rheumatology recommendations |
author_facet |
Catalin Codreanu Ruxandra Ionescu Denisa Predeteanu Elena Rezus Magda Parvu Corina Mogosan Claudiu C. Popescu Simona Rednic |
author_sort |
Catalin Codreanu |
title |
Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemic |
title_short |
Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemic |
title_full |
Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemic |
title_fullStr |
Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemic |
title_full_unstemmed |
Recommendations of the Romanian Society of Rheumatology regarding the management of patients with rheumatic diseases in the context of the SARS-CoV-2 pandemic |
title_sort |
recommendations of the romanian society of rheumatology regarding the management of patients with rheumatic diseases in the context of the sars-cov-2 pandemic |
publisher |
Amaltea Medical Publishing House |
series |
Romanian Journal of Rheumatology |
issn |
1843-0791 2069-6086 |
publishDate |
2020-09-01 |
description |
SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is responsible for the current pandemic, causing so far over 100.000 cases and more than 4500 deaths in Romania. Clinical manifestations are variable, ranging from mild forms (fever, dry cough, dyspnea, tachypnea, asthenia, myalgia) to severe bilateral pneumonia (COVID-19). Generally, patients with inflammatory/autoimmune rheumatic diseases have an increased risk of infections compared to the general population, especially if under treatment with immunosuppressive therapies. In the absence of infection or exposure to SARS-CoV-2, the use of specific drugs (non-steroidal anti-inflammatory drugs – NSAIDs; glucocorticoids - GC; conventional synthetic - csDMARDs, targeted synthetic – tsDMARDs and biologic disease-modifying anti-rheumatic drugs - bDMARDs, denosumab) should be unaffected. In patients with exposure to SARS-Co V-2, but without symptoms of COVID-19, NSAIDs, hydroxychloroquine, sulfasalazine and, in
specific cases, IL-6 inhibitors may be continued, methotrexate, leflunomide, non-anti-IL-6 bDMARDs, tsDMARDs and immunosuppressants should be temporarily discontinued until a negative result for SARS-CoV-2 or for up to 2 weeks asymptomatic state for specific post-epidemiological COVID-19 symptoms. In patients with confirmed or suspected COVID-19 infection, non-anti-IL-6 bDMARDs, tsDMARDs, methotrexate, leflunomide, sulfasalazine
and immunosuppressants must be temporarily discontinued. In such particular cases, IL-6 inhibitors and hydroxychloroquine may be continued, depending on the clinical context. In forms with severe respiratory manifestations, NSAIDs must be stopped. In all cases, non-essential medical consultations and maneuvers should be reduced where appropriate, with optimal use of telemedicine. Social distancing, facial masks and constant hand hygiene
is advised for all patients, according to national and international recommendations. |
topic |
sars-cov-2 rheumatic diseases romanian society of rheumatology recommendations |
url |
https://rjr.com.ro/articles/2020.3/RJR_2020_3_Art-01.pdf |
work_keys_str_mv |
AT catalincodreanu recommendationsoftheromaniansocietyofrheumatologyregardingthemanagementofpatientswithrheumaticdiseasesinthecontextofthesarscov2pandemic AT ruxandraionescu recommendationsoftheromaniansocietyofrheumatologyregardingthemanagementofpatientswithrheumaticdiseasesinthecontextofthesarscov2pandemic AT denisapredeteanu recommendationsoftheromaniansocietyofrheumatologyregardingthemanagementofpatientswithrheumaticdiseasesinthecontextofthesarscov2pandemic AT elenarezus recommendationsoftheromaniansocietyofrheumatologyregardingthemanagementofpatientswithrheumaticdiseasesinthecontextofthesarscov2pandemic AT magdaparvu recommendationsoftheromaniansocietyofrheumatologyregardingthemanagementofpatientswithrheumaticdiseasesinthecontextofthesarscov2pandemic AT corinamogosan recommendationsoftheromaniansocietyofrheumatologyregardingthemanagementofpatientswithrheumaticdiseasesinthecontextofthesarscov2pandemic AT claudiucpopescu recommendationsoftheromaniansocietyofrheumatologyregardingthemanagementofpatientswithrheumaticdiseasesinthecontextofthesarscov2pandemic AT simonarednic recommendationsoftheromaniansocietyofrheumatologyregardingthemanagementofpatientswithrheumaticdiseasesinthecontextofthesarscov2pandemic |
_version_ |
1717819124825980928 |